D2.1 Whitepaper on the platform knowledge base and data standards for in silico drug repurposing
This guidance helps researchers use consistent data and tools when looking for new uses for existing drugs using computer methods. It recommends specific databases, standards, and approaches to make the process more reliable and efficient.
At a glance
Use when
Designing in silico drug repurposing workflows; integrating multi-omics data; selecting data standards or knowledge bases for platform development
Avoid when
Working outside computational repurposing (e.g., de novo drug discovery); when non-standard or proprietary data formats must be used exclusively
Inputs
Heterogeneous biological and clinical data (e.g., sequencing data, GWAS results, high-throughput screening outputs)
Outputs
Harmonized data standards, recommended computational workflows, and guidance on knowledge base usage for drug repurposing
How it works
The whitepaper results from a systematic review of approximately 400 publications and provides strategic recommendations for the REPO4EU consortium. It supports the use of NeDRexDB as a knowledge base, advocates for reproducible and flexible pipelines for disease module discovery, and recommends BioPAX as a standard for representing disease modules. It also suggests adopting established data formats like FASTQ, SAM, and VCF for sequencing data interoperability.
- Project
- REPO4EU
- Funding
- Horizon Europe
- Project status
- Ongoing
- HTA domains
- Clinical Effectiveness, Costs & Economic Evaluation, Organisational aspects
- Categories
- AppraisalDrug RepurposingStandardisation
- Assumptions
- Data from diverse sources can be integrated through standardization; existing databases and tools can be aligned with common formats; adoption of standards improves reproducibility and collaboration
- Strengths
- Based on a systematic review of ~400 sources; provides actionable recommendations tailored to work packages; promotes interoperability through established data standards
- Limitations
- Specific to the REPO4EU project context; may require adaptation for other repurposing initiatives; does not include experimental validation of proposed workflows
- Also known as
- REPO4EU D2.1, D2.1 Whitepaper
Questions this answers
- › How can data from different sources be harmonized for drug repurposing?
- › Which knowledge bases and databases are most suitable for in silico repurposing?
- › What data standards should be used for sequencing and disease module representation?
- › How can reproducible computational pipelines be designed?
- › What are the key challenges in standardizing in silico drug repurposing?
- › Which resources are recommended for specific tasks in the REPO4EU workflow?
References & sources
Related methods
Similar by meaning
Beta record. Generated from the primary source via AI extraction and independent audit, pending final human review.